Search

Compugen Ltd

Uždarymo kaina

2.38 -0.83

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.38

Max

2.41

Pagrindiniai rodikliai

By Trading Economics

Pajamos

663K

-7M

Pardavimai

426K

2.6M

P/E

Sektoriaus vid.

6.324

57.002

Pelnas, tenkantis vienai akcijai

-0.07

Pelno marža

-269.254

Darbuotojai

75

EBITDA

665K

-7M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+107.47% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-09

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-3.8M

221M

Ankstesnė atidarymo kaina

3.21

Ankstesnė uždarymo kaina

2.38

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-16 23:51; UTC

Cryptocurrency Declines Reflect Broader Investor Caution Amid Economic Uncertainties and Geopolitical Tensions.

2026-08-16 23:51; UTC

Japan's GDP growth data highlights economic recovery amid global caution, while U.S. retail sales drop raises concerns over interest rate hikes and geopolitical tensions impact financial stability.

2026-08-16 23:51; UTC

Cryptocurrency and major indices decline amid economic uncertainties, with Bridgewater warning of "crunch time" for capital expenditures and consumer sentiment dropping sharply.

2026-08-16 23:51; UTC

Bitcoin and Ethereum decline as major indices show mixed performance amid cautious market sentiment and concerns over capital expenditures.

2026-08-16 23:51; UTC

NAHB Housing Market Index for August 2026 set to release with forecast of 33.0 amid cautious sentiment and declining builder confidence.

2026-08-16 23:51; UTC

Correlated Moves
Macro News

Bitcoin is lower at $63,022 amid broader market pressures from mixed cryptocurrency movements and recent economic data showing declining U.S. retail sales.

2026-08-16 23:41; UTC

Japan's GDP Growth Preliminary Release Expected to Show Modest +0.02% Year-over-Year Increase Amid Mixed Regional Economic Sentiment

2026-08-16 23:41; UTC

Japan's Q2 GDP Growth Rate Expected at 0.5% Amid Cautious Market Sentiment and Rising Oil Prices

2026-08-16 23:41; UTC

China's July Retail Sales YoY data set for August 17, 2026, forecasts a rise to 1.5%, signaling cautious optimism amid mixed economic indicators.

2026-08-16 23:41; UTC

China's Industrial Production YoY data for July 2026 set to release with a forecasted growth rate of 5.0%, amid cautious market sentiment and concerns over declining fixed asset investment.

2026-08-16 23:41; UTC

Canada's Retail Sales Ex Autos Expected to Rise 0.5% in June Amid Mixed Economic Sentiment

2026-08-16 23:41; UTC

China's Fixed Asset Investment Expected to Decline by 6.2% YoY, Raising Concerns Over Economic Growth

2026-08-16 23:31; UTC

U.S. Industrial Production MoM data for July 2026 set to release on August 18, with cautious optimism amid mixed signals and a forecasted increase of 0.3%.

2026-08-16 23:21; UTC

Philadelphia Fed Manufacturing Index Set for Release Amid Cautious Optimism and Mixed Economic Signals on August 20, 2026.

2026-08-16 23:21; UTC

Canada's New Housing Price Index set for release amid cautious optimism and government infrastructure investments aimed at stabilizing home prices.

2026-08-16 23:11; UTC

China's House Price Index YoY release on August 17, 2026, may reveal ongoing pressures in the housing market amid cautious economic indicators and mixed global market performance.

2026-08-16 23:02; UTC

Correlated Moves

USD/SEK is lower during after-market hours, continuing a downward trend since Friday. Broader market dynamics are influencing the currency pair's movement.

2026-08-16 23:01; UTC

CAD/JPY shows a modest increase in after-hours trading, maintaining an upward trajectory since Friday's close amid a generally positive trading context.

2026-08-16 23:01; UTC

Macro News

The US 30Y Treasury Bond Index is trading lower as mixed China economic data raises concerns about global growth prospects. It pulled back from earlier session highs.

2026-08-16 23:01; UTC

The US 10Y Treasury Bond Index is lower today, trading down from Friday's close. The index remains in the middle of its one-month range.

2026-08-16 23:01; UTC

The CAD/CHF currency pair is higher in after-market hours, reflecting notable strength and unusual activity. It is positioned above its 20-day moving average.

2026-08-16 23:01; UTC

GBP/CHF is trading higher during after-market hours, maintaining a steady upward movement since Friday's close. The asset remains near the upper end of its one-month range.

2026-08-16 23:01; UTC

Gold and silver are trading higher during Sunday’s session, gaining ground since Friday's close. Key economic data from China is expected tomorrow.

2026-08-16 23:01; UTC

Correlated Moves

Gold/NZD is trading higher, supported by rising gold prices against the U.S. dollar and maintaining a position above its 20-day moving average.

2026-08-16 23:01; UTC

Correlated Moves

Gold/SGD is higher today, reflecting a modest increase since Friday's close. The asset remains above its 20-day moving average amid rising silver prices.

2026-08-16 23:01; UTC

Correlated Moves

Gold/JPY is trading higher, reflecting a slight increase since Friday's close. The asset remains above its 20-day moving average and near its one-month range high.

2026-08-16 23:01; UTC

Correlated Moves

Gold/HKD is advancing during the session, reflecting a broader trend as silver also gains. The asset remains above its 20-day moving average.

2026-08-16 23:01; UTC

Correlated Moves

Gold/GBP is trading higher, reflecting a modest advance since Friday's close. The asset remains above its 20-day moving average and near recent highs.

2026-08-16 23:01; UTC

Correlated Moves

Silver/JPY is higher today, supported by a rise in gold and anticipation of key economic data from China.

2026-08-16 23:01; UTC

Correlated Moves

Silver/SGD is rising in the current session, supported by a broader trend in precious metals, with gold also gaining.

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

107.47% į viršų

12 mėnesių prognozė

Vidutinis 5 USD  107.47%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

3

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
help-icon Live chat